Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...
18hon MSNOpinion
Claude joins the ward as Anthropic eyes US healthcare data
In a blog post over the weekend, Anthropic trumpeted the launch of Claude for Healthcare alongside expanded life sciences ...
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany? 12 January, 2026 ? Boehringer Ingelheim today announced a strategic ...
Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
Slomp Filho, M. (2026) Copyright in Generative Artificial Intelligence. Beijing Law Review, 17, 1-10. doi: ...
MINNEAPOLIS, MN, UNITED STATES, January 11, 2026 /EINPresswire.com/ -- Itiliti Health is proud to announce that South ...
All amounts are in Canadian Dollars unless otherwise noted Base Case - US$3,100/oz Au and C$/US$ exchange rate of 1.35: After-Tax NPV : $652 million Payback Period: 2.7 years NPV to Capex: 1.4x ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback